Table 2.
Summary of clinical outcome measures (N = 10).
| Time point | Baseline | End of TPE | 2 weeks post‐TPE | Change at 2 weeks post‐TPE | 6 weeks post‐TPE | Change at 6 weeks post‐TPE | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | Median (range) | Mean (SD) | Median (Range) | Mean (SD) | Median (range) | Median (range) | P‐value | Mean (SD) | Median (range) | Mean (SD) | Median (range) | |
| MG‐ADL | 8.7 (2.0) | 8.5 (6–12) | 3.9 (1.9) | 3.5 (2–7) | 4.4 (2.7) | 3.5 (1–9) | −5.0 (−10 to 1) | <0.0033 | 3.6 (3.5) | 2.0 (0–12) | −5.3 (4.4) | –5.0 (−12 to 3) |
| MG‐QoL15 | 28.8 (9.2) | 25.0 (18–43) | 20.2 (13.8) | 19.5 (3–41) | 16.5 (13.7) | 13.5 (2–41) | –13.0 (−32 to 5) | <0.001 | 12.8 (14.3) | 5.0 (0–36) | –15.2 (11.9) | –18.0 (−32 to 10) |
| MG‐MMT | 29.5 (21.7) | 22.5 (11–81) | 15.3 (19.5) | 8.0 (3–64) | 15.1 (22.0) | 7.0 (2–75) | –10 (−44 to 0) | <0.0001 | 14.2 (23.2) | 7.0 (1–74) | –14.3 (11.7) | −10.0 (−42 to −4) |
| MG‐Composite | 20.7 (4.5) | 21 (12–27) | 10.2 (5.2) | 9.0 (4–19) | 10.0 (6.2) | 8.0 (3–20) | –10.0 (−22 to −3) | <0.0015 | 10.1 (7.7) | 6.0 (3–24) | –10.7 (7.3) | –14.0 (−25 to 4) |
TPE, therapeutic plasma exchange; SD, standard deviation; MG, myasthenia gravis; ADL, Activities of Daily Living; QoL15, Quality of Life 15; MMT, manual muscle test.